SCHEMBL5115129

SCHEMBL5115129

OC1(C#Cc2cccc(Cl)c2)CCN(c2cncc(Cl)n2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.42
HTR2C P28335 3/20 0.42
HTR1A P08908 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GRM5 P41594 7/20 0.42
PTGES O14684 1/20 0.39
HTR2B P41595 2/20 0.38
CHRM4 P08173 1/20 0.37
ADRB1 P08588 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118315 0.87 HTR3E (0.45) KDM4EMEN1ALDH1A1CYP1A2HPGD
SCHEMBL5128709 0.86 GRM5 (0.43) GRM5PTGESPTPN11MAP3K14
SCHEMBL5114711 0.81 GRM5 (0.46) MEN1KMT2AGRM5PTGESMAP3K14
SCHEMBL5117988 0.81 GRM5 (0.46) GRM5PTGESMAP3K14
SCHEMBL5124317 0.81 GRM5 (0.45) GRM5PTGESMAP3K14
SCHEMBL5129125 0.81 GRM5 (0.43) ALDH1A1GRM5PTGESMAP3K14
SCHEMBL5128572 0.81 GRM5 (0.49) GRM5PTGESHTR3AMAP3K14
SCHEMBL5118732 0.80 GRM5 (0.44) ALDH1A1GRM5PTGESPTPN11MAP3K14
SCHEMBL5130025 0.80 GRM5 (0.44) GRM5PTGESMAP3K14
SCHEMBL5119696 0.79 ALDH1A1 (0.50) KDM4EMEN1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1856107-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS Novartis AG (CH) 2007-11-21 EP disclosed
WO-2006089700-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS NOVARTIS AG (CH) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists GRM5, GRIK5, GRM1 HTR2A 390/4885HTR2C 183/4885HTR1A 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.